| Literature DB >> 35812837 |
Ebrahim Mostafavi1,2, Siavash Iravani3, Rajender S Varma4, Mehrdad Khatami5,6, Fatemeh Rahbarizadeh6.
Abstract
Carbon nanotubes (CNTs) with attractive physicochemical characteristics such as high surface area, mechanical strength, functionality, and electrical/thermal conductivity have been widely studied in different fields of science. However, the preparation of these nanostructures on a large scale is either expensive or sometimes ecologically unfriendly. In this context, plenty of studies have been conducted to discover innovative methods to fabricate CNTs in an eco-friendly and inexpensive manner. CNTs have been synthesized using various natural hydrocarbon precursors, including plant extracts (e.g., tea-tree extract), essential oils (e.g., eucalyptus and sunflower oil), biodiesel, milk, honey, and eggs, among others. Additionally, agricultural bio-wastes have been widely studied for synthesizing CNTs. Researchers should embrace the usage of natural and renewable precursors as well as greener methods to produce various types of CNTs in large quantities with the advantages of cost-effectiveness and environmentally benign features. In addition, multifunctionalized CNTs with improved biocompatibility and targeting features are promising candidates for cancer theranostic applications owing to their attractive optical, chemical, thermal, and electrical properties. This perspective discusses the recent developments in eco-friendly synthesis of CNTs using green chemistry-based techniques, natural renewable resources, and sustainable catalysts, with emphasis on important challenges and future perspectives and highlighting techniques for the functionalization or modification of CNTs. Significant and promising cancer theranostic applications as well as their biocompatibility and cytotoxicity issues are also discussed. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35812837 PMCID: PMC9207599 DOI: 10.1039/d2ma00341d
Source DB: PubMed Journal: Mater Adv ISSN: 2633-5409
Fig. 1Some salient advantages and limitations of CNTs.
Some selected examples of CNTs synthesized from biomass using MW irradiation
| CNTs | Catalysts | Synthesis method | Biomass | Ref. |
|---|---|---|---|---|
| MWCNTs (50–200 nm) | Nickel | MW-chemical vapor deposition | Rice husk |
|
| MWCNTs (17–100 nm) | Ferrocene | Oat hulls, hazelnut hulls, wheat straw, and rapeseed cake |
| |
| MWCNTs (50 nm) | Nickel (Ni) | Pine nutshell |
| |
| MWCNTs (50–100 nm) | Mineral matter in char particles from biomass | Gumwood |
| |
| MWCNTs (50–100 nm) | — | MW pyrolysis at low temperature (600 °C); self-extrusion of volatiles | Palm kernel shell cellulose |
|
| MWCNTs (∼20 ± 10 nm, 20 wt% Fe and 50 ± 20 nm, 33.3 wt% Fe) | Fe and Co | MW pyrolysis at low temperature (400–500 °C) | Sugarcane bagasse |
|
Fig. 2Natural precursors or catalysts can be utilized for production and functionalization of CNTs, which can lead to significant advantages and promising applications, while some challenges still remain.
Some plant-based renewable precursors/catalysts for the synthesis of CNTs
| Plant-based resources | CNT-Based nanostructures | Techniques | Sizes (nm) | Ref. |
|---|---|---|---|---|
| Olive oil ( | SWCNTs | Pyrolysis method | ∼27 |
|
|
| CNTs-Cu/ZnO nanocomposites | — | Outer diameter of ∼80 |
|
| Coconut oil ( | MWCNTs | Chemical vapor deposition | Diameter of ∼80–90 |
|
| Eucalyptus oil | SWCNTs | Spray pyrolysis method | Diameter of ∼0.79–1.71 |
|
| Natural palm oil | Vertically aligned CNTs; SWCNTs | Thermal catalytic chemical vapor method | SWCNTs: ∼0.6–1.2 |
|
| Fresh bamboo culms | MWCNTs | Chemical vapor deposition | Diameter of less than 20 |
|
| Rice straw (raw rice straw & neutral pulp) | MWCNTs | Pyrolysis method | Raw rice straw: ∼15–40 |
|
| Neutral pulp: 14.6–47.9 | ||||
| Turpentine oil (pine tree) | MWCNTs | Spray pyrolysis method | ∼15–40 |
|
| Sesame oil ( | Branched nitrogen (N)-doped CNTs | Spray pyrolysis-assisted chemical vapor deposition | ∼30–60 |
|
|
| MWCNTs | Chemical vapor deposition | ∼10 |
|
|
| MWCNTs | Spray pyrolysis method | ∼15–30 |
|
|
| MWCNTs | Chemical vapor deposition | ∼8–15 |
|
Fig. 3(A) Biomedical promises and (B) important challenges of carbon-based nanomaterials.
Some selected examples of CNT-based nanosystems for the delivery of anticancer agents
| Nanosystems | Anticancer agents | Targeting agents | Cancer/tumor | Ref. |
|---|---|---|---|---|
| Chitosan-modified SWCNTs | Doxorubicin | Folic acid | Liver cancer |
|
| MWCNTs functionalized with poly(acrylic acid) and decorated with iron oxide magnetic nanoparticles | Doxorubicin | Folic acid | Human glioblastoma cells |
|
| Polyoxyl 35 castor oil noncovalent modified SWCNTs | Doxorubicin | — | Sarcoma tumor |
|
| Polycitric acid–polyethylene glycol–polycitric acid functionalized MWCNTs | Cisplatin | — | Colon adenocarcinoma tumor |
|
| Functionalized MWCNTs | Gemcitabine | Magnetic particles | Cancer lymph node metastasis |
|
| Functionalized SWCNTs with piperazine–polyethylenimine derivative | siRNA | — | Human breast cancer cells |
|
| Poly(ethylene glycol) grafted polymers–SWCNTs | Doxorubicin | — | HeLa cancer cells |
|
| Radiolabelled SWCNTs | Radionuclide | Thiolated antibodies | Burkitt lymphoma |
|
| Transactivator of transcription (TAT) peptide–chitosan-MWCNTs | Doxorubicin | — | Bel-7402 cells |
|
| Functionalized SWCNTs | Taxoid | Biotin | Leukemia cells |
|
| –CONH–(CH2)6–NH3+Cl− functionalized SWCNTs | Telomerase reverse transcriptase siRNA- | — | Lewis lung tumors; human HeLa cells |
|
| MWCNTs–COOH | Pemetrexed and quercetin | — | Human tumor cells (breast and pancreatic cells) |
|
| MWCNTs coated with silica & chitosan | Doxorubicin | — | Breast cancer |
|
| Glycopolymer decorated MWCNTs | Doxorubicin | Folic acid | Breast cancer |
|
Fig. 4Chitosan–folate conjugated MWCNTs for targeted and sustained delivery of docetaxel anticancer drug to the lung. Reproduced with permission from ref. 141 Copyright 2017 Elsevier.
Fig. 5Chemical structures of the prepared (A) covalently functionalized and (B) non-covalently functionalized SWCNTs. Reproduced with permission from ref. 153 copyright 2020 American Chemical Society. (C) MWCNTs for magnetic lymphatic gemcitabine drug delivery. PO: popliteal lymph node; IN: inguinal lymph node; IL: para-iliac lymph node; RE: renal hilar lymph nodes. Reproduced with permission from ref. 146 Copyright 2011 Elsevier.
Fig. 6Some important factors affecting the safety of CNTs in vivo: (a and b) the effect of CNTs structure on the efficiency of phagocytosis by macrophages and clearing from tissues, in vivo. Reproduced with permission from ref. 159 Copyright 1969, Nature Publishing Group and ref. 160 Copyright 2017 Elsevier. (c) Other factors such as the solubility and aggregation of CNTs influence the safety profile of CNTs in vivo. Reproduced with permission from ref. 159 Copyright 1969, Nature Publishing Group (d) (i) schematic illustration of the process for slicing both SWCNTs and MWCNTs via a vortex fluidic device (VFD) technique, and (ii) double helical topological fluid flow coiling at 4k and 6k rpm, with CNTs slicing at 8k rpm. Reproduced with permission from ref. 161 Copyright 2021 American Chemical Society (e) CNTs produced via greener processes could be a promising, cost-effective, eco-friendly, and leading to improve the biocompatibility and biodistribution of the CNTs, while exploiting the use of natural, renewable and sustainable resources instead of toxic chemicals.
Fig. 7The preparation process of succinylated β-lactoglobuline-functionalized MWCNTs. CDI: N,N′-carbonyldiimidazole, Sblg: succinylated β-lactoglobuline. Reproduced with permission from ref. 170 Copyright 2019 American Chemical Society.
CNTs for cancer theranostic applications: important properties, approaches, and related anticancer pathways
| CNTs-based nanosystems | Properties | – Strong optical absorption |
| – The potential to convert the absorbed light into thermal heat | ||
| – Phototherapy agents | ||
| – High potential for generating reactive oxygen species (ROS) | ||
| – High potential for delivering therapeutic/diagnostic agents | ||
| Approaches | – CNTs-Based drug delivery in cancer therapy | |
| – CNTs mediated photothermal therapy | ||
| – CNTs mediated photodynamic therapy | ||
| – CNTs-Based combined photothermal therapy (photodynamic–photothermal, chemo–photothermal, and immune–photothermal therapy) | ||
| – CNTs for sonodynamic therapy | ||
| – CNTs with anti-metastatic properties and functionality | ||
| Anticancer pathways | – Stimulation of immune system | |
| – Inhibition of cancer/tumor cells | ||
| – Regulation of angiogenesis | ||
| – Photodynamic/photothermal effects | ||
| – Targeted/controlled anticancer therapeutics delivery |
Some notable examples of nanoformulations or nanosystems constructed from CNTs for cancer theranostic applications
| Type of CNTs | Anticancer drugs/agents | Advantages and properties | Ref. |
|---|---|---|---|
| SWCNTs | Doxorubicin | – Improved targeted delivery |
|
| – High intracellular accumulation of drug | |||
| – Suitable cytotoxicity effects with prolonged release behavior | |||
| – High loading potentials | |||
| Paclitaxel | – High efficacy against cell proliferation with enhanced apoptosis rate of anticancer drug in hypoxic environment |
| |
| – Improved chemotherapeutic effects of paclitaxel through hypoxia-inducible factor (HIF)-1a downregulation and apoptosis-related/autophagy-associated proteins upregulation | |||
| Camptothecin | – Improved anticancer therapeutic efficiency with selective inhibitory effects of αVβ3-expressed cancerous cells, while inducing low cytotoxicity to αVβ3-negative cancerous cell up to 3.78- and 3.02-fold in two and three dimensional culture |
| |
| Curcumin | – Improved blood concentration of curcumin (∼18-fold) with remarkable inhibitory effects against cancerous cells and related tumor growth |
| |
| – No noticeable toxicity | |||
| – Enhanced delivery features | |||
| HIF-1α small interfering RNA (siRNA) | – Effective suppression of tumor growth |
| |
| – High specificity/selectivity and low toxicity | |||
| – Selective inhibition of cellular HIF-1α performance | |||
| Cyclin A2 siRNA | – Improved reduction of cell proliferation with induction of apoptosis in chronic myelogenous leukaemia K562 cells |
| |
| – Depletion of cyclin A2 can inhibit the proliferation of targeted cells and stimulate apoptosis of them | |||
| p53 plasmids | – Induction of apoptosis |
| |
| – Over-expression and uptake of the P53 within the MCF-7 cells | |||
| MWCNTs | Methotrexate | – High selectivity with low toxicity |
|
| – pH-Responsive and prolonged release behaviour | |||
| – High efficacy and targeting properties | |||
| Gemcitabine | – Prolonged and pH dependent release behaviour |
| |
| – Low haemolytic toxicity | |||
| – High cytotoxicity against cancerous cells | |||
| – Improved biocompatibility and pharmacokinetics | |||
| Carboplatin | – High cellular uptake with specificity |
| |
| – High cytotoxicity against cancerous cells | |||
| Pemetrexed and quercetin | – Combinatorial therapeutic effects against pancreatic cancer cells |
| |
| – High efficiency for drug delivery | |||
| Recombined ricin A chain | – High induced cancerous cell death effects |
| |
| – High selectivity and targeting properties | |||
| Gold nanostars | – Improved photothermal effects with biocompatibility |
| |
| – High induced cancerous cell death | |||
| CREKA peptide (a tumor homing peptide) | – Targeted antitumor effects |
| |
| – High accumulation of CREKA peptide in tumors (∼6 fold) | |||
| Gemcitabine and lentinan | – Efficient crossing from the cell membrane |
| |
| – Targeted antitumor effects with synergetic activity | |||
| – Low toxicity | |||
| Tamoxifen and lentinan | – Significant inhibitory influences |
| |
| – High apoptosis rate and drug-loading capacity | |||
| Trastuzumab and pertuzumab | – High inhibitory activity against SK-BR-3 (a human breast cancer cell line) with targeting and selectivity properties |
| |
| Doxorubicin | – Efficient drug delivery |
| |
| – Good biocompatibility | |||
| – Internalization of hybrid-CNTs in MCF-7 (a breast cancer cell line) and MDA-MB-231 (a breast cancer cell line) | |||
| Serine/threonine-protein kinase (PLK1) siRNA | – High silencing of polo-like kinase 1 (PLK-1) in HeLa cells |
| |
| – Low toxicity | |||
| – Good biocompatibility | |||
| Hybrid (SWCNTs and MWCNTs) | Non-coding negative siRNA | – Antitumor proliferation effects |
|
| – Targeted cytotoxicity against cancerous cell lines |